Binge Eating Disorder Pipeline Overview and Assessment: H1 2020

DUBLIN, May 13, 2020 /PRNewswire/ -- The "Binge Eating Disorder - Pipeline Review, H1 2020" drug pipelines has been added to's offering.

This pipeline guide provides comprehensive information on the therapeutics under development for Binge Eating Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Binge Eating Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 1, 2, 6 and 1 respectively.

Binge Eating Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


    --  The pipeline guide provides a snapshot of the global therapeutic
        landscape of Binge Eating Disorder (Central Nervous System).
    --  The pipeline guide reviews pipeline therapeutics for Binge Eating
        Disorder (Central Nervous System) by companies and universities/research
        institutes based on information derived from company and
        industry-specific sources.
    --  The pipeline guide covers pipeline products based on several stages of
        development ranging from pre-registration till discovery and undisclosed
    --  The pipeline guide features descriptive drug profiles for the pipeline
        products which comprise, product description, descriptive licensing and
        collaboration details, R&D brief, MoA & other developmental activities.
    --  The pipeline guide reviews key companies involved in Binge Eating
        Disorder (Central Nervous System) therapeutics and enlists all their
        major and minor projects.
    --  The pipeline guide evaluates Binge Eating Disorder (Central Nervous
        System) therapeutics based on mechanism of action (MoA), drug target,
        route of administration (RoA) and molecule type.
    --  The pipeline guide encapsulates all the dormant and discontinued
        pipeline projects.
    --  The pipeline guide reviews latest news related to pipeline therapeutics
        for Binge Eating Disorder (Central Nervous System).

Reasons to Buy

    --  Procure strategically important competitor information, analysis, and
        insights to formulate effective R&D strategies.
    --  Recognize emerging players with potentially strong product portfolio and
        create effective counter-strategies to gain competitive advantage.
    --  Find and recognize significant and varied types of therapeutics under
        development for Binge Eating Disorder (Central Nervous System).
    --  Classify potential new clients or partners in the target demographic.
    --  Develop tactical initiatives by understanding the focus areas of leading
    --  Plan mergers and acquisitions meritoriously by identifying key players
        and it's most promising pipeline therapeutics.
    --  Formulate corrective measures for pipeline projects by understanding
        Binge Eating Disorder (Central Nervous System) pipeline depth and focus
        of Indication therapeutics.
    --  Develop and design in-licensing and out-licensing strategies by
        identifying prospective partners with the most attractive projects to
        enhance and expand business potential and scope.
    --  Adjust the therapeutic portfolio by recognizing discontinued projects
        and understand from the know-how what drove them from pipeline.

Key Topics Covered

    1. Overview
    2. Therapeutics Development
    3. Therapeutics Assessment
    4. Companies Involved in Therapeutics Development
    5. Drug Profiles
    6. Dormant Projects
    7. Discontinued Products
    8. Product Development Milestones

Companies Mentioned

    --  Amygdala Neurosciences Inc
    --  Chronos Therapeutics Ltd
    --  F. Hoffmann-La Roche Ltd
    --  Omeros Corp
    --  OXonium Therapeutics
    --  Seropeutics LLC
    --  Sosei Heptares
    --  Sunovion Pharmaceuticals Inc
    --  Vivus Inc

Drug Profiles

    --  ER (phentermine hydrochloride + topiramate)
    --  ANS-6637
    --  CT-010018
    --  CTDP-002
    --  Dasotraline
    --  OMS-527
    --  RO-5256390
    --  SERx-480

Featured News & Press Releases in 2019

    --  Nov 20, 2019: New Clinical data demonstrate VIVUS' Qsymia is effective
        at reducing Binge Eating in patients with Binge-Eating Disorder or
        Bulimia Nervosa
    --  Jul 30, 2019: Sunovion announces acceptance by the U.S. FDA of the new
        drug application for Dasotraline for the treatment of adults with
        moderate-to-severe binge eating disorder
    --  May 02, 2019: Sunovion to present data on dasotraline at the 2019
        American Psychiatric Association Annual Meeting

For more information about this drug pipelines report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets